The mRNA cancer vaccine biologic lines market is projected to grow from USD 585.4 million in 2026 to USD 1,738.6 million by 2036, at a CAGR of 11.5%. Phase II will dominate with a 38.0% market share, while in-house will lead the manufacturing mode segment with a 58.0% share.